Ethnic skin, specifically patients with Fitzpatrick skin phototypes IV to VI, is particularly susceptible to complications related to
A post-hoc analysis of major semaglutide trials confirmed no significant differences in depression or suicidal behavior compared to placebo
Chen, W., Zhang, Y., Wang, T., & Lin, X
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population